You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T790M Mutation

Showing 1 - 25 of 4,270
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Moscow, Russian Federation
      Federal State Budgetary Institution National Medical Research Ce
    Mar 29, 2022

    NSCLC With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis, Failed Tyrosine Kinase Inhibitors Trial in Seoul

    Active, not recruiting
    • Non-Small Cell Lung Cancer With EGFR T790M Mutation
    • +2 more
    • Seoul, Korea, Republic of
      Department of Medicine, Samsung Medical Center, Sungkyunkwan Uni
    Aug 8, 2021

    Lung Cancer Trial (Lazertinib 240 mg)

    Approved for marketing
    • Lung Cancer
    • Lazertinib 240 mg
    • (no location specified)
    Feb 15, 2022

    NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • Kashiwa, Chiba, Japan
    • +3 more
    Jan 31, 2023

    Non Small Cell Lung Cancer Trial in Worldwide (AZD9291)

    Active, not recruiting
    Has Results
    • Non Small Cell Lung Cancer
    • La Jolla, California
    • +43 more
    Nov 25, 2022

    Osimertinib for HK Chinese With Metastatic T790M Mutated

    Completed
    • Non-small Cell Lung Cancer
    • Hong Kong, China
    • +3 more
    Sep 7, 2021

    Osimertinib in Advanced Non-Small Cell Lung Cancer EGFR-T790M

    Completed
    • Non Small Cell Lung Cancer
    • Oviedo, Asturias, Spain
    • +30 more
    Jun 1, 2022

    Lung Tumors, EGFR Gene Mutations Trial in Hwasun (Osimertinib)

    Completed
    • Lung Neoplasms
    • EGFR Gene Mutations
    • Hwasun, Jeonnam, Korea, Republic of
      Chonnam National University Hwasun Hospital
    Aug 1, 2021

    Either EML4-ALK Gene Rearrangements or T790M EGFR Mutation in

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
      • Hollywood, Florida
      • +1 more
      Sep 29, 2021

      Non Small Cell Lung Cancer Trial in China (XZP-5809-TT1 Tablet)

      Recruiting
      • Non Small Cell Lung Cancer
      • XZP-5809-TT1 Tablet
      • Beijing, Beijing, China
      • +4 more
      Mar 17, 2021

      NSCLC Trial in Beijing, Nanjing, Suzhou (BPI-7711 Capsule)

      Completed
      • Non-small Cell Lung Cancer
      • BPI-7711 Capsule
      • Beijing, Beijing, China
      • +3 more
      May 13, 2022

      NSCLC Trial in Australia, China, Korea, Republic of (AZD9291)

      Active, not recruiting
      Has Results
      • Non-Small Cell Lung Cancer
      • Kogarah, Australia
      • +29 more
      Oct 20, 2022

      Non Small Cell Lung Cancer (NSCLC) Trial in India (Osimertinib)

      Completed
      Has Results
      • Non Small Cell Lung Cancer (NSCLC)
      • Hyderabad, India
      • +6 more
      May 10, 2021

      NSCLC Trial in Spain (Osimertinib)

      Completed
      • Non-Small Cell Lung Cancer
      • Barcelona, Spain
      • +6 more
      Nov 25, 2020

      Lung Cancer Trial in Boston, Nashville

      Active, not recruiting
      • Lung Cancer
        • Boston, Massachusetts
        • +1 more
        Dec 28, 2022

        Lung Cancer Stage IV, EGFR T790M Trial in Seoul (Lazertinib)

        Not yet recruiting
        • Lung Cancer Stage IV
        • EGFR T790M
        • Seoul, MA, Korea, Republic of
          Samsung Medical Center
        Jan 26, 2023

        Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M Trial in Seoul (Lazertinib)

        Not yet recruiting
        • Metastatic Lung Non-Small Cell Carcinoma
        • EGFR T790M
        • Seoul, Korea, Republic of
          Samsung Medical Center
        May 18, 2022

        (Korea Osimertinib Real World Evidence Study to Assess Safety

        Completed
        • Non-Small Cell Lung Cancer
          • South Korea, Korea, Republic of
            Research Site
          Sep 8, 2020

          Lung Cancer, Non-small Cell, EGFR T790M, EGFR Gene Mutation Trial in Shanghai (Almonertinib, Pemetrexed, Carboplatin)

          Unknown status
          • Lung Cancer, Non-small Cell
          • +2 more
          • Shanghai, Shanghai, China
            Cancer hospital Fudan University
          Oct 15, 2020

          EGFR T790M, Osimertinib, NSCLC Trial in Beijing (Osimertinib)

          Recruiting
          • EGFR T790M
          • +3 more
          • Beijing, Beijing, China
            Junling Li
          Jul 21, 2022

          NSCLC Trial in China (Drug intervention)

          Active, not recruiting
          • NSCLC
          • Drug intervention
          • Nanjing, Jiangsu, China
          • +4 more
          Sep 28, 2020

          Non Small Cell Lung Cancer Metastatic Trial in Worldwide (Osimertinib, Bevacizumab)

          Active, not recruiting
          • Non Small Cell Lung Cancer Metastatic
          • Dublin, Ireland
          • +24 more
          Aug 23, 2022

          Lung Cancer Trial in Worldwide (T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG)

          Completed
          Has Results
          • Lung Cancer
          • T790M+ Testing
          • +4 more
          • Buenos Aires, Argentina
          • +200 more
          Nov 10, 2021

          Advanced NSCLC Patients With T790M Trial in Beijing (Alflutinib)

          Unknown status
          • Advanced NSCLC Patients With T790M
          • Beijing, China
            cancer hospital Chinese academy of medical sciences
          Jan 2, 2020

          Negative T790M Mutation and Met Amplification Trial in Beijing (Glumetinib)

          Unknown status
          • Negative T790M Mutation and Met Amplification
          • Beijing, Beijing, China
            Beijing Cancer Hospital
          Apr 7, 2020